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Abstract
Background: To study the effects of zoledronic acid (ZA) on the vasculogenic mimicry of osteosarcoma cells in vitro.
Methods: A Three-dimensional culture of LM8 osteosarcoma cells on a type I collagen matrix was used to
investigate whether osteosarcoma cells can develop vasculogenic mimicry, and to determine the effects of ZA on
this process. In addition, the cellular ultrastructural changes were observed using scanning electron microscopy
and laser confocal microscopy. The effects of ZA on the translocation of RhoA protein from the cytosol to the
membrane in LM8 cells were measured via immunoblotting.
Results: ZA inhibited the development of vasculogenic mimicry by the LM8 osteosarcoma cells, decreased
microvilli formation on the cell surface, and disrupted the F-actin cytoskeleton. ZA prevented translocation of RhoA
protein from the cytosol to the membrane in LM8 cells.
Conclusions: ZA can impair RhoA membrane localization in LM8 cells, causing obvious changes in the
ultrastructure of osteosarcoma cells and induce cell apoptosis, which may be one of the underlying mechanisms
by which the agent inhibits the development of vasculogenic mimicry by the LM8 cells.
Background
Solid malignant tumors require a robust blood supply to
support growth and metastasis. For many years, tumor
angiogenesis was regarded as the only means by which a
tumor could acquire an adequate blood supply. In 1999,
Maniotis et al. discovered a new type of blood vessel in
human malignant uveal melanoma [1]. The blood vessel
walls were created by deformed malignant melanoma
cells and stromal cells. Because their structure was simi-
lar to regular blood vessels, they were considered to
have vasculogenic mimicry (VM). Subsequent research
found that tumors that harbor VM, such as malignant
melanoma, synovial sarcoma, mesothelial sarcoma, and
ovarian cancer, possess the following characteristics: a
high degree of malignancy, uncommitted differentiation
or bi-directional differentiation status, rapid growth, and
a high rate of metastasis [2-5].
Osteosarcoma is the most common malignant bone can-
cer in adolescents and children. It usually has a high
degree of malignancy, a rapid growth rate, and a tendency
to metastasize. These characteristics resemble many of the
tumors known to develop VM. Zoledronic acid (ZA) is a
representative biphosphate, a class of compounds which
are known to be potent anti-absorptives. Bisphosphonates
have been widely used to treat hypercalcemia and ostealgia
due to osteoporosis or osteitis deformans, and to treat
malignant tumors that have metastasized to the bone [6].
Aside from the potent anti-absorptive effects of the com-
pounds, biphosphates have also recently been recognized
as anti-tumor agents [7-9]. However, the effects of ZA on
the development of vasculogenic mimicry in osteosarcoma
have not been reported. In the present study, we used a
three-dimensional culture of LM8 osteosarcoma cells
grown on a type I collagen matrix to investigate whether
these cells develop vasculogenic mimicry, and to deter-
mine the effects of ZA on this process.
Methods
1. Materials
ZA was obtained from Novartis (Basel, Switzerland) and
clodronic acid from Berlex Laboratories(New Jersey,
USA). The murine osteosarcoma cell line (LM8) was
obtained from the Center of Experimental Animals at
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The RPMI 1640 medium was purchased from Hyclone
(Thermo Scientific, Logan, Utah, USA) and fetal bovine
serum from Minhai Biotechnology Company (Lanzhou,
China). The CCK-8 kit was obtained from Dojindo
Laboratories (Kumamoto, Japan) and collagenase from
Wako Pure Chemical Industries (Osaka, Japan). Mouse
tail type I collagen was obtained from Shengyou Bio-
technology Inc. (Hangzhou, China) and the Annexin V
FITC kit from Jingmei Biotechnology Inc. (Shenzhen,
China). FOH and GGOH were purchased from Sigma
(Saint Quentin Fallavier, France), and the inhibitor of
RhoA from Calbiochem (San Diego, CA, USA). FITC-
conjugated phalloidin was obtained from Sigma (St.
Louis, MO, USA). All other reagents were the purest
grade available.
2. Cell culture
Animal care and surgery were approved by the technical
scientific and ethical committees of Union Hospital,
Tongji Medical College, Huazhong University of Science
and Technology and were performed under national and
European regulations (Law by Decree n. 116/92). The
LM8 osteosarcoma cells were maintained in an RPMI
1640 medium supplemented with 10% fetal bovine serum
at 37°C under 5% CO2. Cells were subcultured when they
reached 70-80% confluence by 0.25% trypsin digestion.
When the newly plated cells reached the exponential
growth phase, they were used for experiments.
3. Examination of cell proliferation using the CCK-8 assay
The LM8 cells in the exponential growth phase were
plated in 96-well plates at a density of 5 × 10
4 cells/mL
in the RPMI 1640 medium, which was then replaced
with a fresh basal medium containing different concen-
trations of ZA (1, 5, and 10 μmol/L) 24 hours after plat-
ing. Cell proliferation was analyzed following the
manufacturer’s protocol. Briefly, after 24 hours treat-
ment, 10 μL of the CCK-8 solution was added to each
well, and then the cells were cultured for another
4 hours. At the termination of the experiment, the plate
was read in a spectrometer at 450 nm to determine the
absorbance of each well ("A value”).
4. Preparation of type I collagen and 3-D cell culture
Type I collagen isolated from mouse tails was dissolved
in 0.013 mol/L HCl to achieve a concentration of 5 mg/
mL. The type I collagen solution (200 L) was mixed
with 674 μLH 2O in an eppendorf tube on ice. The mix-
ture was added to 26 μLN a O H( 0 . 1m o l / L )a n dm i x e d
well. The new mixture was added to 100 μL of the 10 ×
RPMI 1640 medium and mixed well. In a 12-well plate,
cover slides were placed in each well. Fifty μLo ft h e
medium mixture was added onto each slide and
incubated at 37°C for one hour until the type I collagen
gel solidified. LM8 cells were plated at a density of 5 ×
10
5 cells/mL on the gel plaques. After the cells attached,
a basal medium with or without ZA was added. The
growth of LM8 cells on type I collagen plaques was
monitored under an inverted contrast microscope.
Twenty-four hours later, LM8 cells were harvested from
3D gels, by incubation at room temperature in collage-
nase at 10 mg/ml for 5 min with shaking, for prolifera-
tion assay.
5. Observation by scanning electron microscopy
LM8 cells in control and treatment groups were cul-
tured on top of collagen gel plaques for 24 hours, and
then fixed by 2.5% glutaraldehyde for 2-4 hours. They
were subsequently washed with PBS 3 times and fixed
with 1% osmium tetroxide for 1-1.5 hours. The cells
were then washed with PBS for 30 minutes. After dehy-
dration with an alcohol gradient, the samples were
i m m o b i l i z e db yac o n d u c t i v ea d h e s i v ea n ds p r a y e dw i t h
carbon and gold. The samples were observed under a
scanning electron microscope and images were taken.
An MIAS-200 image analyzer was used to measure the
maximum diameter of the cells, the number and length
of microvilli, and the number and length of pseudopo-
dia. The values are shown as the means ± standard
deviation from three independent experiments.
6. Morphology and quantification of cell apoptosis
To assess cellular apoptosis, LM8 cells were plated on 6-
well plates at a density of 5 × 10
5 cells/well. After cells
attached, they were exposed to 5 μmol/L ZA (or the
vehicle control) for 24 hours. The cover slides were
removed and stained as instructed by the manufacturer
of the TUNEL assay kit. We also assessed apoptosis
using Annexin V/PI staining. For this study, the LM8
cells were treated with 0, 1, or 5 μmol/L ZA for 24
hours. The cells were then trypsinized and pelleted by
centrifugation. Cell pellets were washed with phosphate
buffer twice and resuspended in 250 μL binding buffer
at a density of 1 × 10
6 cells/mL. One-hundred μLo ft h e
cell suspension was analyzed by flow cytometry after
cells were stained with 5 μL Annexin V-FITC and 10 μL
PI solution (20 μg/mL) to detect apoptosis.
7. Observation of the cell cytoskeleton by laser confocal
microscopy
LM8 cells treated with ZA for 24 hours were washed with
PBS twice and then fixed with 4% formaldehyde at 4°C
for 10 minutes. The cells were then treated with 0.2%
Triton X-100 at room temperature for 10 minutes. BSA
(0.5%) was added to the cells for 30 minutes to non-
specifically block the binding sites; then cells were
washed twice with PBS. FITC-conjugated phalloidin
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37°C. The cells were then washed with PBS twice and
with distilled water once, and slides were mounted using
50% glycerol. Cell morphology was examined under a
laser confocal microscope.
8. RhoA Translocation Assay
To determine the membrane-bound (GTP-ase active
form) of RhoA, LM8 cells were serum starved for 16
hours and then exposed to ZA or clodronic acid for 24 h.
To obtain membrane and cytosolic fractions, the cells
were washed and homogenized in a buffer containing 50
mM Tris-HCl, pH 7.4, 1 mM ethylene glycol tetraacetic
acid, 1 mM ethylene diamine tetraacetic acid, 10 μg/mL
leupeptin, 10 μg/mL aprotinin, 5 mM benzamidine HCl,
10 μg/mL soybean trypsin inhibitor, and 1 mM phenyl-
methylsulfonyl fluoride by ultrasonic polytron. The cell
extract was centrifuged at 800 g for 5 minutes. The super-
natant was then collected and further centrifuged at
15,000 g for 15 minutes at 4°C. The supernatant was cen-
trifuged again at 100,000 g for 1 hour at 4°C, and then the
supernatant was collected as the cytosolic fraction, and the
pellet, as the membrane fraction, was then resuspended.
Equal amounts (10 μg) of protein from each fraction were
used to perform western blot analysis for RhoA.
9. Statistical analyses
The SPSS11.5 statistical software package was used to
analyze the data. To compare the differences between
the control and treatment groups, a Student’st - t e s tw a s
used. For the comparison of multiple groups, ANOVA
was used. Differences with p values less than 0.05 were
regarded as statistically significant.
Results
1. 5 μmol/L of ZA does not affect LM8 cell proliferation
The results of the CCK-8 assay showed that the absor-
bance (A value) of LM8 cells treated with the vehicle
c o n t r o lo r1 ,5 ,o r1 0μmol/L ZA for 1 hour was 0.899
± 0.020, 0.875 ± 0.008, 0.864 ± 0.016, and 0.829 ± 0.017,
respectively. The data were derived from three indepen-
dent experiments. There were no significant differences
between the A values of the control group and the
groups exposed to treatment with ZA at 1 or 5 μmol/L.
However, 10 μmol/L ZA did significantly decrease the
proliferation of the cells. Therefore, 5 μmol/L of ZA was
used for the subsequent 3-D culture experiments.
2. ZA prevents the development of vasculogenic mimicry
by osteosarcoma cells in vitro
Under inverted contrast microscopy, LM8 cells were
polygonal with a full cytoplasm. Cells grown in a 3-D
type-I collagen matrix culture after 24 hours partially
formed long spindle shapes. Cell protrusions were
obvious, and the cells formed connective structures
resembling blood vessels. Exposure to 5 μmol/L ZA
completely inhibited the formation of the blood vessel-
like structures (Figures 1A and 1B). CCK-8 assay
showed no significant differences between the A values
of the control group(0.882 ± 0.012) and the 5 μmol/L
ZA group(0.869 ± 0.017) (p < 0.05). The data were
derived from three independent experiments.
3. The effects of ZA on the cellular structure of
osteosarcoma cells
Scanning electron microscopy revealed that osteosarcoma
cells formed blood vessel-like structures, and this forma-
tion was blocked by ZA treatment, confirming the obser-
vations obtained under contrast microscopy (Figures 1C
and 1D). In addition, scanning electron microscopy also
showed the presence of microvilli structures in the lumen
of the blood vessel-like tubes formed by the osteosarcoma
cells (Figure 1E). There were more microvilli on the mem-
brane of LM8 cells in the control group compared with
the ZA treatment group. The microvilli intertwined with
each other, and some cells had filopodia with splitting
ends. The size of the LM8 cells decreased after ZA treat-
ment, and both the number and length of filopodia and
microvilli decreased following ZA treatment (p < 0.05,
Figure 2 and Table 1).
4. ZA induces apoptosis in LM8 cells
LM8 cells were treated with 0, 1, or 5 μmol/L ZA for 24
hours. Cellular apoptosis was analyzed by TUNEL stain-
ing. The results showed that 5 μmol/L ZA induced exten-
sive apoptosis (brown staining demonstrating the nuclei of
apoptotic cells, Figure 3), while there were only a few
apoptotic cells present in the control group. Flow cytome-
try using Annexin V-FITC/PI staining quantified the
apoptotic cell number. These results showed that the per-
centage of apoptotic cells in the control cells, and those
treated with 1 or 5 μmol/L ZA was 1.84 ± 0.57%, 1.92 ±
1.13%, or 18.72 ± 3.14%, respectively. The difference
between the 5 μmol/L ZA group and the other two groups
was statistically significant (F = 364.438, p < 0.01), while
there was no statistically significant difference between the
control and 1 μmol/L ZA groups (Figure 3).
5. The effects of ZA on the cytoskeleton of LM8
osteosarcoma cells
F-actin is one of the major components of the cytoskele-
ton. Phalloidin can specifically bind to F-actin. Therefore,
fluorescence-conjugated phalloidin was used to detect
the cytoskeleton in treated and untreated LM8 cells.
U n d e ral a s e rc o n f o c a lm i c r o scope, F-actin was distinct
in the control group, showing a compact and directional
alignment with obvious fibrous tension. On the other
hand, F-actin was aligned loosely in the 5 μmol/L ZA
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tional characteristics of the F-actin (Figure 4). Our results
indicate that ZA caused the disruption of the cytoskele-
ton structure of LM8 cells.
6. ZA prevents RhoA membrane localization in LM8 cells
Since the small GTPase RhoA must be targeted to the
plasma membrane for its activation, we examined the
effects of ZA on the translocation of RhoA protein from
the cytosol to the membrane in LM8 cells after separa-
tion of cytosolic and membrane fractions. In untreated
cells, equivalent amounts of RhoA are present in both
fractions. Treatment of LM8 cells with ZA (10 μM) for
24 h decreased membrane localization of RhoA with a
reciprocal concomitant increase in RhoA in the cytosol
(Figure 5A). By contrast, treatment with 10 μM clodronic
acid for 24 h has no the same effects. In addition, we
observed that the inhibiting effect of ZA on the RhoA
Figure 1 The effect of ZA on the development of vasculogenic mimicry by LM8 osteosarcoma cells in vitro.T h eL M 8o s t e o s a r c o m ac e l l s
were seeded on type I collagen gel plaques. They were treated with the vehicle control or 5 μmol/L ZA for 24 hours. The cellular structure was
observed under an inverted contrast microscope (A and B, X100) or with a scanning electron microscope (C and D, X2000). E: Zoomed-in area of C.
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GGOH(20 μM), but not FOH(20 μM) (Figure 5B).
Discussion
In the traditional 2-D cell culture system, cells are cul-
tured under an isolated and artificial environment that
is distinct from their native physiological environment.
Therefore, their biological characteristics may change
dramatically. Type I collagen is the most abundant com-
ponent of the extracellular matrix. It is soluble under
acidic conditions. When neutralized, it can solidify to a
gel form at 37°C. Type I collagen is the most widely
used matrix in 3-D cell culture. Cells that grow on type
I collagen gel attach to the extracellular matrix and
demonstrate growth behaviors that more closely resem-
ble their in vivo growth. More important, cells that
grow embedded in the type I collagen gel show a similar
phenotype as that of in vivo tumor cells. Therefore, this
model has been regarded as a good platform to study
the growth behaviors of tumor cells in vitro.
However, one weakness of the model is that the cells
grow dimensionally on different plates, therefore making
observations with a regular optical microscope difficult. For
this reason, we have improved our 3-D culture methodol-
ogy to use a thin layer of collagen to provide a 3-D growth
platform, thus making optical microscopy possible. Our
new methodology also distinguishes itself from traditional
gel-embedded culture models by accelerating the formation
of osteosarcoma vasculogenic mimicry. Twelve hours after
cell plating, regular vasculogenic mimicry can be observed,
whereas 3-5 days are needed if the cells are grown using a
conventional gel-embedded model. In the current study, we
successfully established a thin-layer 3-D culturing system
using a type I collagen matrix to grow LM8 cells. Vasculo-
genic mimicry was developed, demonstrating that osteosar-
coma cells possess metamorphic abilities and can exhibit
vasculogenic mimicry in vitro.
Previous studies have shown that ZA can effectively
inhibit the proliferation of osteosarcoma cells and induce
apoptosis [1,10]. In the present study, we showed that 5
μmol/L ZA had no inhibitory effect on cell proliferation
by the CCK-8 assay. Therefore, the inhibition of vasculo-
genic mimicry by the 5 μmol/L concentration of ZA was
not due to inhibition of cell proliferation. Both optical
and scanning electron microscopy showed that the 5
μmol/L concentration of ZA inhibited the development
of vasculogenic mimicry by the osteosarcoma cells.
Using the TUNEL assay, we demonstrated that
5 μmol/L ZA induced apoptosis in LM8 cells. The data
was validated and apoptosis was further quantified by
flow cytometry using Annexin V-FITC/PI staining.
Taken together, our data showed that although the 5
μmol/L concentration of ZA did not have any significant
effect on cell proliferation, it promoted apoptosis.
Figure 2 The effect of ZA on the ultrastructures of LM8 cells grown on type I collagen gel. The LM8 osteosarcoma cells were seeded on
type I collagen gel plaques and treated with the vehicle control (A) or 5 μmol/L ZA (B) for 24 hours. The cellular ultrastructures were observed
with a scanning electron microscope (X4000).
Table 1 Quantification of the cellular structure of LM8 osteosarcoma cells
Control 5 μmol/L ZA P value
Maximum cell diameter (μm) 450.46 ± 60.29 328.28 ± 48.76 P = 0.021
Number of microvilli 24.86 ± 2.68 6.48 ± 1.16 P = 0.000
Length of microvilli (μm) 87.21 ± 23.41 52.47 ± 13.18 P = 0.013
Number of filopodia 11.93 ± 0.76 4.12 ± 0.45 P = 0.000
Length of filopodia (μm) 112.56 ± 32.34 76.96 ± 14.78 P = 0.018
The values are shown as the means ± standard deviation from three independent experiments.
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filopodia on the cell surface. Filopodia helps cells to
move, attach, absorb nutrients, endocytose, and support
cellular structures. Our current study showed that the
number of microvilli and filopodia decreased dramatically
following ZA treatment as observed under a scanning
electron microscope. The cytoskeleton is an important
component of the cellular architecture that determines
the structure of the cell. The cytoskeleton connects with
the plasma membrane and nuclear membrane proteins,
Figure 3 The effect of ZA on LM8 cell apoptosis. The LM8 osteosarcoma cells were cultured on type I collagen gel and treated with the vehicle
control (A) or 5 μmol/L ZA (B) for 24 hours (X400). Apoptotic cells were stained using the TUNEL assay (brown). The non-apoptotic cells were stained
blue. Alternatively, the LM8 cells treated with the vehicle control (C), 1 μmol/L ZA (D), or 5 μmol/L ZA (E) for 24 hours were analyzed by flow cytometry
after staining with Annexin V-FITC/PI. The table shows the mean ± SE from n=3independent experiments, where each quadrant represents the
percentage of cells in early apoptosis (Lower right, LR), late apoptosis (Upper right,U R ) ,n e c r o s i s( Upper left, UL), and healthy cells (Lower left, LL).
Figure 4 The effect of ZA on F-actin in LM8 cells. The LM8 osteosarcoma cells were cultured on type I collagen gel and treated with the
vehicle control (A) or 5 μmol/L ZA (B) for 24 hours. F-actin was detected by green fluorescent phalloidin staining and confocal microscopy.
Fu et al. BMC Musculoskeletal Disorders 2011, 12:146
http://www.biomedcentral.com/1471-2474/12/146
Page 6 of 8and is important in supporting the normal cell shape.
Moreover, the cytoskeleton is involved in cell mobility
and division, and forms the basic structure for trans-
membrane signal transduction. Cells rely on the cytoske-
leton to survive, divide, grow, and interact with other
cells. Actin is present in cells in either the conjugated
form (F-actin) or the isolated form (G-actin). G-actin is a
single-unit globular protein that is soluble in the cyto-
plasm. In contrast, F-actin is fibrous and is the major
component of the cytoskeleton. F-actin is more involved
in biological processes than G-actin. Microfilaments are
comprised of two strands of F-actin that have combined
in a helical form. In the resting state, the two forms of
actin (F- and G-actin) are in equilibrium to maintain the
morphology and functions of the cell. In the current
study, F-actin in LM8 osteosarcoma cells treated with ZA
lost its fibrous and directional characteristics as indicated
by laser confocal microscopy, resulting in disruption of
the cytoskeletal structure. Overall, our results indicated
that ZA can induce apoptosis in LM8 cells, decrease the
number of microvilli and filopodia on the cell surface,
and disrupt the structure of F-actin in the cytoskeleton.
All of these effects may contribute to the inhibitory
effects of ZA on the development of vasculogenic mimi-
cry, future investigations should clarify this point.
However, our study has several limitations. First, only
an in vitro approach was used in the study. We therefore
cannot ensure how apoptosis and vasculogenic mimicry
are connected. Thereby, to confirm the capability of LM8
to organize a vasculogenic mimicry network, an in vivo
or ex-vivo model should be established in future study.
Second, ZA is a nitrogen-containing bisphosphonate and
could inhibit the expression of Rho GTPase geranylgera-
nylation, which family has been shown to regulate many
aspects of intracellular actin dynamics (lamellipodia, filo-
podia, actin retraction, phagocytosis, cell morphology)
[11], in Saos-2 osteoblast-like cells [12], MDA-MB-231
breast cancer cell line [13] and multiple myeloma
RPMI8226 cell line [14]. In this study, We found that ZA
impairs RhoA translocation from the cytosol to the mem-
brane in LM8 cells, while clodronic acid (a no nitrogen-
containig bisphosphonate) has no same effects. This
pharmacodynamic aspect provides a potential mechan-
ism to explain how ZA is capable to determine F-actin
cytoskeleton and ultrastructural modifications (thus
affecting vasculogenic mimicry development). Research
on the molecular mechanisms underlying VM and the
functional relevance will improve our understanding of
this process and may ultimately contribute to the devel-
opment of more accurate treatment modalities [15].
Conclusions
ZA can prevent RhoA membrane localization in LM8
cells, causing obvious changes in the ultrastructure of
osteosarcoma cells and induce cell apoptosis, which may
be one of the underlying mechanisms by which the agent
inhibits the development of vasculogenic mimicry by the
LM8 cells.
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Figure 5 ZA prevents RhoA membrane localization in LM8
cells. Treatment of LM8 cells with ZA (10 μM) or clodronic acid (10
μM) for 24 hours (A). In the presence or absence of GGOH(20 μM)
or FOH(20 μM) for 48 hours(A). Cells were extracted and separated
intocytosolic and membrane fractions to detect RhoA by
immunoblotting as described in the experimental section. These
results are representative of three independent experiments.
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